Navigation Links
Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
Date:1/9/2008

ogical and other surgical and medical procedures. Omeros has three ongoing PharmacoSurgery clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.

Forward-looking Statements

This press release contains "forward-looking statements." These statements include, but are not limited to, those regarding Omeros' proposed initial public offering and expectations regarding its clinical development activities and the clinical benefits of its product candidates. These forward-looking statements are based on the current intent and expectations of the management of Omeros. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Omeros' actual results and the timing and outcome of events may differ materially from those expressed in or implied by the forward-looking statements because of risks associated with Omeros' clinical development activities, regulatory oversight, intellectual property rights and other risks. Omeros undertakes no obligation to update any forward-looking or other statements in this press release, whether as a result of new information, future events or otherwise. SOURCE Omeros Corporation


'/>"/>
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Genelex Corporation Defends Consumers Right to Obtain DNA Information:
2. Pharmos Corporation Completes Initial Closing of Private Placement
3. Pharmos Corporation Announces Board and Management Changes
4. Environmental Tectonics Corporation Announces Sale of Monoplace Hyperbaric Chambers
5. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
6. LifeCell Corporation Schedules 2008 Financial Guidance Release and Conference Call; January 7, 2008 at 10:00 A.M. Eastern
7. Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
10. FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products
11. Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... (PRWEB) November 28, 2014 The report ... for all the important sub-segments of the market, in ... It maps the growth rates and market sizes for ... poised to witness rapid growth. It also includes analysis ... These company profiles include the financial performances, product portfolios, ...
(Date:11/27/2014)... 2014 First articles published ... Elsevier , a world-leading provider of scientific, ... to announce the launch of a new journal: ... The launch of Extreme Mechanics Letters ... forefront of applied sciences such as micro and nanotechnologies, ...
(Date:11/26/2014)... The report on the Global Smart Sensor Market in ... revenue forecasts and market trends. It expects the market ... to 2018. At the projected rate, the market is ... 2018. , Browse through the Global Smart Sensor Market ... market segmentation and in-depth analysis supported by a list ...
(Date:11/26/2014)... 2014 The announced sales of three healthcare ... looking to expand in non-healthcare areas, says Kalorama Information. ... research firm says that  Siemens is the third largest ... of the IVD market , with 5.5 billion in ... composition would likely affect IVD market shares.  ...
Breaking Biology Technology:Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 2Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 3Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 4Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 5Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 2Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 3Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 2Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 3Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 4Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2
... Inc. today announced that data from its phase 1/2 ... be highlighted in an oral presentation at the 50th ... in San Francisco, California, on December 9, 2008. , ... of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with ...
... BioMarin Pharmaceutical,Inc. (Nasdaq: BMRN ) today announced that ... update at the Piper,Jaffray Healthcare Conference in New York City ... Interested parties may access a ... of the BioMarin website, http://www.BMRN.com . A,replay of the ...
... JOLLA, Calif., Nov. 25 TorreyPines Therapeutics, Inc.,(Nasdaq: ... from Eli Lilly & Company,a reduction in certain royalty ... sales of TorreyPines, clinical-stage compounds NGX426 and tezampanel,should either ... rate will be reduced three percentage points and the ...
Cached Biology Technology:Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting 2Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting 3BioMarin to Present at the Piper Jaffray Healthcare Conference 2TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel 2
(Date:11/21/2014)... 20, 2014 C-Labs LLC, a leading provider ... Things (IoT), today announced the appointment of John ... Previously a strategic advisor to the firm, Mr. Traynor ... Traynor is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)... 18, 2014   EyeLock Inc. , a ... MorphoTrust USA (Safran), a leading U.S. ... a strategic partnership to offer comprehensive biometric identity ... (MVA), airport screening and financial services markets. ... serves consumers through a nationwide network of 1,100 ...
(Date:11/7/2014)... Researchers led by Dr. Debra Auguste, associate professor, ... at The City College of New York, have ... treatment for one of the most aggressive forms ... (TNBCs) have a high mortality rate owing to ... effective therapeutic options. However, Professor Auguste,s team, discovered ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... Researchers have long known that humans lack a key enzyme ... even plants -- that reverses severe sun damage. For ... at the atomic level to repair sun-damaged DNA. The ... prevention. In the early online edition of the journal ...
... Eeva Karjalainen, of the Finnish Forest Research Institute, Metla, "feel ... not many of us know that there is also scientific ... and other natural, green settings can reduce stress, ... Forest visits may also strengthen our immune system by increasing ...
... (SACRAMENTO, Calif.) A shared decision-making process would assist ... challenging and controversial choices presented when infants are born ... are being considered for elective corrective surgery, a new ... instances in which infants are born with conditions that ...
Cached Biology News:Researchers discover how key enzyme repairs sun-damaged DNA 2Study recommends that parents, physicians share decisions in sex development disorder surgery 2Study recommends that parents, physicians share decisions in sex development disorder surgery 3Study recommends that parents, physicians share decisions in sex development disorder surgery 4